Topic: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

http://www.medscape.com/viewarticle/817589_1

Any advice or comments I give are based on personal experiences and knowledge and are my opinions only, they are not to be substituted for professional medical advice. Please seek professional advice from a qualified doctor or medical professional.

Re: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Appears that those patients in high risk group benefitted greatly from adjuvant therapy. 
BTW: It is easy to sign in for free with Medscape.
Hugs,
Marion

THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER

Re: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Very cool article Gavin, thanx for sharing!

Survivor of cholangiocarcinoma (2009), thyroid cancer (1999), and breast cancer (1994).

My comments, suggestions, and opinions are based only on my personal experience as a cancer survivor. Please consult a physician for professional guidance.

Re: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Hi,everyone,
this is the abstract Gavin posted above if you cannot open it.

Abstract

Background and Aim Cholangiocarcinoma patients usually have poor treatment outcome and a high mortality rate. The role of adjuvant chemotherapy (AC) is controversial. Our study aimed to evaluate benefits of AC in resectable cholangiocarcinoma patients.

Methods A retrospective study included 263 patients who underwent curative resection in Srinakarind University Hospital. These patients had pathological reports showing a clear margin (R0) or microscopic margin (R1) of lesion-free tissue.

Results There were 138 patients who received AC. This group had a significantly lower mean age than patients not receiving adjuvant chemotherapy (NAC) group (57.7 ± 8.5 vs 60.4 ± 9.0 years, P = 0.01). The level of serum albumin above 3 g/dL was more common in AC group than the NAC one (87.7% vs 79.2%, P = 0.04). Patients who received AC had significantly longer overall median survival time (21.6 vs 13.4 months, P = 0.01). Patients with a combination of gemcitabine and capecitabine regimen had the longest survival time (median overall survival time of gemcitabine and capecitabine 31.5, 5-fluorouracil and mitomycin 17.3, 5-fluorouracil alone 22.2, capecitabine alone 21.6, and gemcitabine alone 7.9 months, P = 0.02). Benefits of AC were likely to be found in patients who had high-risk features, that is, high level of carbohydrate antigen 19–9, advanced stage, T4 stage, lymph node involvement, and R1 margin.

Conclusions AC significantly prolongs survival time in resectable cholangiocarcinoma patients, particularly in the high risk group.

Please know that my personal opinion is not intended nor implied to be a substitute for professional medical advice. If  provided, information are for educational purposes.Consult doctor is a MUST for changing of treatment plans.

Re: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Thanks for posting Gavin. Mark hits a couple of the high risk markers so it makes me doubly glad we decided to go ahead with it.

KrisV

Any advice given is based on my experiences and should not be substituted for any medical recommendations. Please speak with your provider before making any changes.

Re: Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients.

Nice post